中文名称：莫索尼啶
  • 4-氯-N-(4,5-二氢-1H-咪唑-2-基)-6-甲氧基-2-甲基-5-嘧啶胺; 莫索尼定,不带盐酸; 莫索尼定
  • Moxonidine
  • 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamin; bdf5895; be5895; BDF-5895; 4-Chloro-6-Methoxy-2-Methyl-5-(2-Imidazolin-2-YL)Aminopyrimidine; 4-Chloro-N-(4,5-Dihydro-1H-Imidazol-2-YL)-6-Methoxy-2-Methyl-5-Pyrimidinamine; 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine
  • 75438-57-2
  • C9H12ClN5O
  • 241.6775
  • InChI=1/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)
  • 莫索尼啶 75438-57-2
  • 1.52g/cm3
  • 364.7°C at 760 mmHg
  • 174.3°C
  • 1.66E-05mmHg at 25°C
  • 结晶，熔点217-219℃(分解)。盐酸莫索尼定(Moxonidine Hydrochloride)：C9H12ClN5O?xHCl。[75438-58-3]。从异丙醇-乙醚结晶，熔点189℃。
  • 通过刺激中枢突触前α2-受体而起效。其降压效果和钙拮抗剂硝苯地平和ACE抑制剂卡托普利相似。用于原发性高血压。